Overview

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
Details
Lead Sponsor:
Bayer
Treatments:
Niacinamide
Sorafenib